Skip to content

Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality

To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00871832
Enrollment
200
Registered
2009-03-30
Start date
2007-05-31
Completion date
2010-03-31
Last updated
2013-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia

Keywords

hyperglycemia, HgA1c, mortality

Brief summary

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.

Interventions

None listed

Sponsors

Staten Island University Hospital
CollaboratorOTHER
Northwell Health
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speak English that give consent.

Design outcomes

Primary

MeasureTime frameDescription
morbidity and mortalityat time of reviewlooking to see if HbA1C correlates with morbidity (i.e. sepsis, renal failure, length of stay) or death

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026